<DOC>
	<DOCNO>NCT03038009</DOCNO>
	<brief_summary>The purpose study determine whether 12-month prophylactic treatment pantoprazole superior 1-month therapy without major cardiovascular event ( MACE ) increase significantly , prevention dual antiplatelet therapy ( DAPT ) -induced upper gastrointestinal ( GI ) mucosal injury coronary artery bypass graft ( CABG ) surgery . The potentially serious harm DAPT gastroduodenal mucosa assess esophagogastroduodenoscopy ( EGD ) .</brief_summary>
	<brief_title>Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft</brief_title>
	<detailed_description>Endoscopic evaluation gastroduodenal mucosal injury : Based modify Lanza score , new endoscopic evaluation system establish DACAB-GI-1 study include 6 grade mucosal injury . Grade 0 : normal mucosa ; Grade 1 : erythema petechia ; Grade 2 : 1 2 erosive lesion ; Grade 3 : 3 10 erosive lesion ; Grade 4 : 10 erosive lesion small ulcer ( diameter : 3-5mm ) ; Grade 5 : ulcer great 5 mm diameter . Comprehensive result gastroduodenal mucosal injury mark G0-5 ( G : gastro ) D0-5 ( D : duodeno ) together . Mild injury define level II le . Severe injury define level III V , treat proton pump inhibitor ( PPI ) decrease risk upper GI bleeding . The new level system follow : Level 0 : G0D0 ; Level I : G1D0-1/G0D1 ; Level II : G2D0-2/G0-1D2 ; Level III : G3D0-3/G0-2D3 ; Level IV : G4D0-4/G0-3D4 ; Level V : G5D0-5/G0-4D5 . Sample size justification : Until , publish data reference available efficacy pantoprazole concomitant use DAPT . The result preliminary study ( DACAB-GI-1 ) show percentage serious gastroduodenal mucosal lesion ( Level III-V ) patient treat PPIs 1 , 3 6 month 36.76 % , 28.45 % 17.65 % , respectively . Therefore , efficacy difference pantoprazole estimate 18 % 2 group . The average incidence gastroduodenal mucosal injury estimate 36 % control group ( 1-month therapy pantoprazole ) , correspond incidence experimental group ( 12-month therapy pantoprazole ) estimate 18 % . The determination minimal sample size following : Group sample size 93 experimental group 93 control group achieve 80 % power detect difference group proportion -18 % . The proportion experimental group assume 36 % null hypothesis 18 % alternative hypothesis . The proportion control group 36 % . The test statistic use Pearson Chi-Squared test . The significance level test target 0.05 . The significance level actually achieve design 0.0522 . Considering 10 % lose and/or drop-out rate , final sample size estimate 104 experimental group control group , respectively . The total sample size less 208 .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Each patient meet inclusion criterion none exclusion criterion study : 1 . Provision inform consent prior study specific procedure . 2 . CABG surgery perform first time . 3 . Need 12month DAPT ( aspirin 100mg qd plus clopidogrel 75mg qd aspirin 100mg qd plus ticagrelor 90mg bid depend randomisation ) immediately follow CABG surgery accord guideline . 4 . Concomitant use pantoprazole ( 40mg qd ) least 1 moth follow CABG surgery . 5 . Willing undergo EGD twice year ( 6th 12th month follow CABG surgery , respectively ) . 6 . Willing undergo 13CUBT prior CABG surgery . Patients enter study follow exclusion criterion fulfil . 1 . History previous active peptic ulcer within 3 month prior enrollment . 2 . Planned use PPI treat gastricacid associate disease ( e.g . gastroesophageal reflux disease , GERD ) 3 . Contraindications aspirin , clopidogrel , ticagrelor pantoprazole use ( e.g . know allergy ) 4 . Anticipated concomitant oral intravenous therapy strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor CYP3A4 substrates narrow therapeutic index , stop course study . Strong inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir CYP3A4 substrates narrow therapeutic index : quinidine , simvastatin dos &gt; 40mg daily lovastatin dose &gt; 40mg daily . 5 . Need chronic oral anticoagulant therapy chronic lowmolecularweight heparin . 6 . History previous intracerebral bleeding time , GI bleed within past 3 month prior enrollment , major surgery within 30 day prior enrollment . 7 . Known moderate severe liver disease ( e.g . gastroesophageal varix , ascites and/ clinical sign coagulopathy ) 8 . Renal failure require dialysis . 9 . Women childbearing potential willing use medically accept method contraception consider reliable judgement investigator OR woman positive pregnancy test enrolment randomisation OR woman breastingfeeding . 10 . Inability patient understand and/or comply study procedure and/or follow , opinion investigator , OR condition , opinion investigator , many render patient unable complete study . 11 . Any condition opinion investigator would make unsafe unsuitable patient participate study ( eg , longterm concomitant treatment nonsteroidal antiinflammatory drug [ NSAIDs ] ) , condition outside atherothrombotic study area life expectancy le 2 year base investigator 's judgement . 12 . Paticipation another clinical study investigational product within 28 day prior enrolment previous randomization investigational product another ongoing clinical study . Participation previous study clopidogrel tigagrelor .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary Artery Bypass Graft</keyword>
	<keyword>Dual Antiplatelet Therapy</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Mucosal Injury</keyword>
	<keyword>Proton Pump Inhibitor</keyword>
</DOC>